Stockscreener 앱 받기
4.75
2.98%
-0.1461
시간 외 거래:
4.75
Pluri Inc 주식(PLUR)의 최신 뉴스
Pluri Inc. sets date for 2025 shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com
Pluri acquires 71% stake in Kokomodo - Food Business News
Pluri Inc. acquires majority stake in Kokomodo Ltd. By Investing.com - Investing.com Canada
Pluri Acquires 71% Of Kokomodo To Advance Climate-Resilient Cultivated Cacao Production - Nasdaq
Pluri Inc. acquires majority stake in Kokomodo Ltd. - Investing.com
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan
Pluri Inc. enters agreement, issues pre-funded warrants - Investing.com Australia
Pluri Inc. enters agreement, issues pre-funded warrants By Investing.com - Investing.com Canada
Pluristem stock soars to 52-week high, hits $6.63 By Investing.com - Investing.com South Africa
Pluristem stock soars to 52-week high, hits $6.63 - Investing.com Australia
DarioHealth Announces CFO Transition - Benzinga
Pluri Inc. subsidiary loses $4.2 million NIAID contract By Investing.com - Investing.com Canada
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com Australia
Pluri IncPluri Biotech Receives Termination Notice From Niaid Of ContractSEC Filing - marketscreener.com
Analyzing X4 Pharmaceuticals (NASDAQ:XFOR) & Pluri (NASDAQ:PLUR) - Defense World
Pluri Inc. (NASDAQ:PLUR) Short Interest Update - Defense World
Pluri’s immune cell expansion technologies gain patents - Yahoo Finance
Pluri Announces Expansion of Intellectual Property Portfolio wit - GuruFocus
Pluri secures patents for cancer cell therapy expansion tech By Investing.com - Investing.com South Africa
Pluri Inc. Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - MarketScreener
Pluri secures patents for cancer cell therapy expansion tech - Investing.com India
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel - TradingView
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news
Pluristem stock touches 52-week low at $4 amid market challenges By Investing.com - Investing.com South Africa
Pluristem stock touches 52-week low at $4 amid market challenges - Investing.com
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
Pluri Inc. (NASDAQ:PLUR) Sees Large Decrease in Short Interest - Defense World
Pluri Inc. sets date for 2025 annual shareholder meeting By Investing.com - Investing.com Canada
Pluri Inc. sets date for 2025 annual shareholder meeting - Investing.com India
Revolutionary Cell Therapy Preservation: Teknova's New PluriFreeze System Transforms Development Process - StockTitan
Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom - openPR
Plurilock Security (CVE:PLUR) Shares Down 5% – Here’s What Happened - Defense World
Using cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech? - The Jerusalem Post
Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Forecast: Ke... - WhaTech
Pluri Inc. partners with Hemafund for radiation emergency response By Investing.com - Investing.com Canada
Pluri Inc. and Hemafund partner for radiation emergency pre By Investing.com - Investing.com Canada
Pluri signs deal to help Ukraine's radiation emergency preparedness - The Pharma Letter
Pluri, Hemafund Sign Exclusive Collaboration Deal on Potential Radiation Treatment; Shares Rise - Marketscreener.com
0.39%
3.66%
자본화:
|
볼륨(24시간):